Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Jun;17(6):862-7.
doi: 10.1093/neuonc/nou350. Epub 2015 Jan 7.

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

Eudocia Q Lee  1 , David A Reardon  1 , David Schiff  1 , Jan Drappatz  1 , Alona Muzikansky  1 , Sean A Grimm  1 , Andrew D Norden  1 , Lakshmi Nayak  1 , Rameen Beroukhim  1 , Mikael L Rinne  1 , Andrew S Chi  1 , Tracy T Batchelor  1 , Kelly Hempfling  1 , Christine McCluskey  1 , Katrina H Smith  1 , Sarah C Gaffey  1 , Brendan Wrigley  1 , Keith L Ligon  1 , Jeffrey J Raizer  1 , Patrick Y Wen  1
Affiliations
Clinical Trial

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

Eudocia Q Lee et al. Neuro Oncol. 2015 Jun.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Neuro Oncol. 2015 Dec;17(12):1650. doi: 10.1093/neuonc/nov201. Epub 2015 Sep 19. Neuro Oncol. 2015. PMID: 26386410 Free PMC article. No abstract available.

Abstract

Background: Panobinostat is a histone deacetylase inhibitor with antineoplastic and antiangiogenic effects in glioma that may work synergistically with bevacizumab. We conducted a multicenter phase II trial of panobinostat combined with bevacizumab in patients with recurrent high-grade glioma (HGG).

Methods: Patients with recurrent HGG were treated with oral panobinostat 30 mg 3 times per week, every other week, in combination with bevacizumab 10 mg/kg every other week. The primary endpoint was a 6-month progression-fee survival (PFS6) rate for participants with recurrent glioblastoma (GBM). Patients with recurrent anaplastic glioma (AG) were evaluated as an exploratory arm of the study.

Results: At interim analysis, the GBM arm did not meet criteria for continued accrual, and the GBM arm was closed. A total of 24 patients with GBM were accrued prior to closure. The PFS6 rate was 30.4% (95%, CI 12.4%-50.7%), median PFS was 5 months (range, 3-9 months), and median overall survival (OS) was 9 months (range, 6-19 months). Accrual in the AG arm continued to completion, and a total of 15 patients were enrolled. The PFS6 rate was 46.7% (range, 21%-73%), median PFS was 7 months (range, 2-10 months), and median OS was 17 months (range, 5 months-27 months).

Conclusions: This phase II study of panobinostat and bevacizumab in participants with recurrent GBM did not meet criteria for continued accrual, and the GBM cohort of the study was closed. Although it was reasonably well tolerated, the addition of panobinostat to bevacizumab did not significantly improve PFS6 compared with historical controls of bevacizumab monotherapy in either cohort.

Trial registration: ClinicalTrials.gov NCT00859222.

Keywords: anaplastic glioma; antiangiogenesis,; bevacizumab; glioblastoma; panobinostat.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Overall survival (solid line) and progression-free survival (dashed line) in the glioblastoma arm.
Fig. 2.
Fig. 2.
Progression-free survival in the anaplastic glioma arm by R132H IDH1 mutation status (dashed line for participants with negative staining for R132H IDH1 mutation and solid line for participants with positive staining for R132H IDH1 mutation).
Fig. 3.
Fig. 3.
Overall survival in the anaplastic glioma arm by R132H IDH1 mutation status (dashed line for participants with negative staining for R132H IDH1 mutation and solid line for participants with positive staining for R132H IDH1 mutation).
See this image and copyright information in PMC

References

    1. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16:Suppl 4:iv1–63. - PMC - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. - PubMed
    1. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27(35):5874–5880. - PubMed
    1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. - PubMed
    1. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–4740. - PubMed

Publication types

MeSH terms

Associated data